Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ALGS
#3397
Aligos Therapeutics, Inc. Common Stock
7.030
0
+1.30%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+1.30%
Monthly Change
-19.10%
6 month change
-28.19%
Year Change
-28.19%
Previous Close
6.940
0
Open
7.030
0
Bid
Ask
Low
7.030
0
High
7.030
0
Volume
2
Markets
US Stock Market
Healthcare
ALGS
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
News
Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress
Aligos Therapeutics stock rises on Phase 2 HBV study progress
Aligos reports progress on Phase 2 hepatitis B drug study
Aligos therapeutics appoints James Hassard as chief commercial officer
Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline
Aligos reports synergistic weight loss effect with THR-β agonist
Aligos Therapeutics, Inc. (ALGS) Presents at Jefferies London Healthcare Conference 2025 Transcript
Aligos Therapeutics stock reaffirmed Buy at H.C. Wainwright
Tracking Baker Brothers Portfolio – Q2 2025 Update
Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study